May 2nd, 2024 - Stonegate Healthcare Partners is providing an update on the publication of its report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease.
Pruritus affects approximately 8.2% of the global population, with a significant impact on the quality of life for individuals with skin conditions and liver diseases. 40% of patients with liver disease suffer from chronic pruritus. PBC presents a high unmet need, with 72% of patients experiencing severe chronic nocturnal pruritus. The report identifies the limitations of current treatments, emphasizing the urgent need for innovative therapeutic approaches.
Stonegate's research focused on 164 companies in the pruritus space, resulting in the identification of 23 companies with the potential to revolutionize PBC management. The report highlights key players leading the charge in transformative therapies. Companies featured in the report include Connect Biopharma (NasdaqGM: CNTB), Ironwood Pharmaceuticals (NasdaqGS: IRWD), Mirum Pharmaceuticals (NasdaqGM: MIRM), and Tharimmune (NasdaqCM: THAR).
Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies.
